Apatinib inhibits tumour progression and promotes antitumour efficacy of cytotoxic drugs in oesophageal squamous cell carcinoma

Abstract

Oesophageal carcinoma (ESCA) is one of the most common digestive tract malignant tumours in the world. 1 Oesophageal squamous cell carcinomas (ESCC) is the main pathological type in China, especially in Henan province where there is a higher incidence. ESCC in its early stages often affects its functions only slightly, with no obvious symptoms. When they have clinical manifestations, most of the patients are in the advanced stage and have missed the chance of surgical treatment. Chemotherapy is an essential method to advanced

An exploratory clinical trial of apatinib combined with intensity‐modulated radiation therapy for patients with unresectable hepatocellular carcinoma

“…Additionally, this study included patients who had been refractory with postoperative progression after surgery or interventional therapy, including those who had been treated with second or later‐line of previous systemic treatment regimens (63.6%), whereas the SHARP, ORIENTAL, and REFLECT studies enrolled patients who had not received previous systemic therapy. However, the present study has shown that a median PFS was 7.8 months, besides, the OS rates at 6‐ and 12‐month respectively were 96.7% and 66.2%, indicating that the survival benefit was significantly better than that reported in previous studies 9,10,12,16 . Although this was an exploratory study with small sample size, it showed that the novel treatment modality of apatinib combined with IMRT provides better survival benefits for patients with uHCC.…”

“…However, the present study has shown that a median PFS was 7.8 months, besides, the OS rates at 6-and 12-month respectively were 96.7% and 66.2%, indicating that the survival benefit was significantly better than that reported in previous studies. 9,10,12,16 Although F I G U R E 2 Progression-free survival (A) and overall survival (B) of patients in first-line and second or later-line groups. this was an exploratory study with small sample size, it showed that the novel treatment modality of apatinib combined with IMRT provides better survival benefits for patients with uHCC.…”

Targeted therapy for head and neck cancer: signaling pathways and clinical studies

“…Apatinib is a novel selective VEGFR-2 inhibitor that inhibits the proliferative ability of thyroid carcinoma and squamous cell carcinoma in vivo and vitro and has been identified in multiple studies. 281 , 282 In a tumor xenograft model, mice benefited from either apatinib alone or apatinib in combination with cytotoxic drugs. 283 Tumor angiogenesis was also suppressed after apatinib treatment.…”

“…EGFR epidermal growth factor receptor, EGF epidermal augmentum factor, MET mesenchymal-epithelial transition factor, JAK Janus-activated kinase, STAT signal transducer and activator of transcription, AKT serine/threonine-specific protein kinase, mTOR mammalian target of rapamycin, CDK cyclin-dependent kinase, VEGF vascular endothelial growth factor, mAb monoclonal antibody, RET rearranged during transfection, p phosphorylation carcinoma in vivo and vitro and has been identified in multiple studies. 281,282 In a tumor xenograft model, mice benefited from either apatinib alone or apatinib in combination with cytotoxic drugs. 283 Tumor angiogenesis was also suppressed after apatinib treatment.…”

Folate Receptor 4-Expressing T cell Is Associated with Disease-Free Survival in Patients with Esophageal Squamous Cell Carcinoma

“…Currently, immunotherapeutic monoclonal antibodies offer hope for the treatment of ESCC. With the release of clinical trial results such as CheckMate 577, Keynote-590, Keynote-180, and Keynote-181, PD-1/PD-L1 antibodies have been developed as a first-line treatment for advanced ESCC [ 5 ]. However, poor overall response, susceptibility to drug resistance, and lack of predictive biomarkers remain challenges for current immunotherapy for ESCC.…”